Porter KR - Search Results

1

Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques.

Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, Murphy GS, Weiss WR, Hayes CG. Raviprakash K, et al. Among authors: porter kr. J Gen Virol. 2000 Jul;81(Pt 7):1659-67. doi: 10.1099/0022-1317-81-7-1659. J Gen Virol. 2000. PMID: 10859370

2

A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques.

Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, Ewing D, Wu SJ, Bass S, Punnonen J, Porter K. Raviprakash K, et al. Virology. 2006 Sep 15;353(1):166-73. doi: 10.1016/j.virol.2006.05.005. Epub 2006 Jun 30. Virology. 2006. PMID: 16814355 Free article.

3

A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.

Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, Sedegah M, Hayes C, Porter K, Raviprakash K. Chen L, et al. J Virol. 2007 Nov;81(21):11634-9. doi: 10.1128/JVI.00996-07. Epub 2007 Aug 22. J Virol. 2007. PMID: 17715224 Free PMC article.

4

A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.

Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K. Raviprakash K, et al. J Virol. 2008 Jul;82(14):6927-34. doi: 10.1128/JVI.02724-07. Epub 2008 May 14. J Virol. 2008. PMID: 18480438 Free PMC article.

5

Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques.

Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. Simmons M, et al. Among authors: porter kr. J Virol. 2006 Oct;80(19):9577-85. doi: 10.1128/JVI.00284-06. J Virol. 2006. PMID: 16973561 Free PMC article.

6

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial.

Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, Wu SJ, Sun P, Kochel T, Raviprakash K, Hayes CG, Porter KR. Beckett CG, et al. Among authors: porter kr. Vaccine. 2011 Jan 29;29(5):960-8. doi: 10.1016/j.vaccine.2010.11.050. Epub 2010 Nov 25. Vaccine. 2011. PMID: 21111785 Clinical Trial.

7

Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine.

Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, Teneza-Mora N, Raviprakash K. Porter KR, et al. Vaccine. 2012 Jan 5;30(2):336-41. doi: 10.1016/j.vaccine.2011.10.085. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22085548

8

Tetravalent DNA vaccine product as a vaccine candidate against dengue.

Porter KR, Teneza-Mora N, Raviprakash K. Porter KR, et al. Methods Mol Biol. 2014;1143:283-95. doi: 10.1007/978-1-4939-0410-5_17. Methods Mol Biol. 2014. PMID: 24715294

9

Nucleic acid (DNA) immunization as a platform for dengue vaccine development.

Porter KR, Raviprakash K. Porter KR, et al. Vaccine. 2015 Dec 10;33(50):7135-40. doi: 10.1016/j.vaccine.2015.09.102. Epub 2015 Oct 14. Vaccine. 2015. PMID: 26458805 Review.

10

Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys.

Raviprakash K, Ewing D, Simmons M, Porter KR, Jones TR, Hayes CG, Stout R, Murphy GS. Raviprakash K, et al. Among authors: porter kr. Virology. 2003 Oct 25;315(2):345-52. doi: 10.1016/s0042-6822(03)00542-7. Virology. 2003. PMID: 14585337 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page